Anthrax vaccine - Harvard University/Soligenix

Drug Profile

Anthrax vaccine - Harvard University/Soligenix

Alternative Names: DNI-rPA; SGX-204; VeloThrax

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard University
  • Developer Soligenix
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Anthrax

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Anthrax in USA (Parenteral)
  • 19 Aug 2014 Anthrax vaccine - Harvard University/Soligenix is available for licensing in World as of 19 Aug 2014.
  • 07 Aug 2014 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top